18 Works

Additional file 1 of Assessment of socio-relational self-efficacy in breast cancer patients: Italian validation of the social relationship coping efficacy scale (SRCE-I)

Samantha Serpentini, Giulia Silvestri, Antonio Catarinella, Grazia Cristaldi, Caterina Borgese, Giuseppe Deledda, Samuela Sommacal, Letizia Iannopollo, Vincenzo Calvo, Lucia Ronconi & Thomas V. Merluzzi
Additional file 1: Regression analyses and English version of the Social Relationship Coping Efficacy Scale.

Additional file 1 of Assessment of socio-relational self-efficacy in breast cancer patients: Italian validation of the social relationship coping efficacy scale (SRCE-I)

Samantha Serpentini, Giulia Silvestri, Antonio Catarinella, Grazia Cristaldi, Caterina Borgese, Giuseppe Deledda, Samuela Sommacal, Letizia Iannopollo, Vincenzo Calvo, Lucia Ronconi & Thomas V. Merluzzi
Additional file 1: Regression analyses and English version of the Social Relationship Coping Efficacy Scale.

Additional file 2 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 2: Figure S2. Stratification of patients by IMDC and Meet-URO scores at nivolumab treatment start (N = 556)*. * Treatment line / patients: 2nd/384, 3rd/118, 4th/41, 5th/11, 6th/1, 7th/1. Abbreviations: PG prognostic group, RG risk group.

Additional file 2 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 2: Figure S2. Stratification of patients by IMDC and Meet-URO scores at nivolumab treatment start (N = 556)*. * Treatment line / patients: 2nd/384, 3rd/118, 4th/41, 5th/11, 6th/1, 7th/1. Abbreviations: PG prognostic group, RG risk group.

Assessment of socio-relational self-efficacy in breast cancer patients: Italian validation of the social relationship coping efficacy scale (SRCE-I)

Samantha Serpentini, Giulia Silvestri, Antonio Catarinella, Grazia Cristaldi, Caterina Borgese, Giuseppe Deledda, Samuela Sommacal, Letizia Iannopollo, Vincenzo Calvo, Lucia Ronconi & Thomas V. Merluzzi
Abstract Background Social relationship coping efficacy (SRCE) represents the ability to maintain or enhance social relationships in the context of serious illness. The purpose of the current study was to confirm the factor structure, psychometric properties, and utility of the Italian version of the SRCE scale. Methods 181 breast cancer patients completed the SRCE-Italian (SRCE-I), the Cancer Behavior Inventory–Brief/Italian (CBI–B/I), quality of life (QOL) measures (EORTC QLQ-C30; EORTC QLQ-BR23), and the Hospital Anxiety and Depression...

Additional file 1 of Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Additional file 1: Appendix I.

Additional file 3 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 3: Figure S3. Kaplan Meiers curves showing the prognostic role of nephrectomy in mRCC patients according to the type of nephrectomy.

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy

Margherita Rimini, Andrea Casadei-Gardini, Giovanni Brandi, Francesco Leone, Lorenzo Fornaro, Nicoletta Pella, Nicola Silvestris, Francesco Montagnani, Sara Lonardi, Eleonora Lai, Eva Galizia, Daniele Santini, Andrea Palloni, Roberto Filippi, Gianluca Masi, Giuseppe Aprile, Massimo Aglietta, Giorgio Frega, Elisabetta Fenocchio, Caterina Vivaldi, Maria Antonietta Satolli, Francesca Salani, Mario Scartozzi, Luca Faloppi, Antonio Pellino … & Alessandro Cucchetti
Biliary tract cancer’s (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians’ confidence in the use of new technologies and molecular analysis turned out to be of interest and potentially influencing survival. After applying a random-effect model, the relationship between each clinical variable on the main outcome was investigated through multilevel mixed-effects logistic regression. The risk-standardized outcomes were calculated for each centre involved. In the unadjusted cohort the median...

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Abstract Background Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines and targeted therapy, but it is still unclear in the immunotherapy era. Methods We investigated the Meet-URO-15 study dataset of 571 pretreated mRCC patients receiving nivolumab as second or further lines about the prognostic role of the previous nephrectomy (received in either the localized or...

Additional file 1 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 1: Figure S1. Stratification of patients by IMDC score at disease onset and nivolumab treatment start (N = 493)*. * Missing data for 63 patients. Abbrevviations: PG prognostic group, RG risk group.

Additional file 1 of Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Additional file 1: Appendix I.

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy

Margherita Rimini, Andrea Casadei-Gardini, Giovanni Brandi, Francesco Leone, Lorenzo Fornaro, Nicoletta Pella, Nicola Silvestris, Francesco Montagnani, Sara Lonardi, Eleonora Lai, Eva Galizia, Daniele Santini, Andrea Palloni, Roberto Filippi, Gianluca Masi, Giuseppe Aprile, Massimo Aglietta, Giorgio Frega, Elisabetta Fenocchio, Caterina Vivaldi, Maria Antonietta Satolli, Francesca Salani, Mario Scartozzi, Luca Faloppi, Antonio Pellino … & Alessandro Cucchetti
Biliary tract cancer’s (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians’ confidence in the use of new technologies and molecular analysis turned out to be of interest and potentially influencing survival. After applying a random-effect model, the relationship between each clinical variable on the main outcome was investigated through multilevel mixed-effects logistic regression. The risk-standardized outcomes were calculated for each centre involved. In the unadjusted cohort the median...

Additional file 1 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 1: Figure S1. Stratification of patients by IMDC score at disease onset and nivolumab treatment start (N = 493)*. * Missing data for 63 patients. Abbrevviations: PG prognostic group, RG risk group.

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Abstract Background Nephrectomy is considered the backbone of managing patients with localized and selected metastatic renal cell carcinoma (mRCC). The prognostic role of nephrectomy has been widely investigated with cytokines and targeted therapy, but it is still unclear in the immunotherapy era. Methods We investigated the Meet-URO-15 study dataset of 571 pretreated mRCC patients receiving nivolumab as second or further lines about the prognostic role of the previous nephrectomy (received in either the localized or...

Additional file 3 of The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi, Marco Maruzzo, Ugo De Giorgi, Umberto Basso, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Emanuela Fantinel, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Francesco Boccardo, Lucia Fratino, Stefania Pipitone, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini … & Sebastiano Buti
Additional file 3: Figure S3. Kaplan Meiers curves showing the prognostic role of nephrectomy in mRCC patients according to the type of nephrectomy.

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Abstract Background Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the comparative analysis of MTB networks, but these are rarely reported. This manuscript summarizes the state-of-art of 16 active Italian MTBs, as it emerges from an online survey curated by Alliance Against Cancer (ACC). Main text Most MTBs (13/16) are exclusively supported through local Institutional...

Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini & Ruggero De Maria
Abstract Background Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the comparative analysis of MTB networks, but these are rarely reported. This manuscript summarizes the state-of-art of 16 active Italian MTBs, as it emerges from an online survey curated by Alliance Against Cancer (ACC). Main text Most MTBs (13/16) are exclusively supported through local Institutional...

Assessment of socio-relational self-efficacy in breast cancer patients: Italian validation of the social relationship coping efficacy scale (SRCE-I)

Samantha Serpentini, Giulia Silvestri, Antonio Catarinella, Grazia Cristaldi, Caterina Borgese, Giuseppe Deledda, Samuela Sommacal, Letizia Iannopollo, Vincenzo Calvo, Lucia Ronconi & Thomas V. Merluzzi
Abstract Background Social relationship coping efficacy (SRCE) represents the ability to maintain or enhance social relationships in the context of serious illness. The purpose of the current study was to confirm the factor structure, psychometric properties, and utility of the Italian version of the SRCE scale. Methods 181 breast cancer patients completed the SRCE-Italian (SRCE-I), the Cancer Behavior Inventory–Brief/Italian (CBI–B/I), quality of life (QOL) measures (EORTC QLQ-C30; EORTC QLQ-BR23), and the Hospital Anxiety and Depression...

Registration Year

  • 2022
    18

Resource Types

  • Collection
    6
  • Image
    6
  • Text
    6

Affiliations

  • Istituto Oncologico Veneto
    18
  • Candiolo Cancer Institute
    14
  • University of Bologna
    12
  • Humanitas University
    12
  • European Institute of Oncology
    12
  • Centro di Riferimento Oncologico
    12
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
    12
  • IRCCS Humanitas Research Hospital
    12
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    12
  • Sapienza University of Rome
    10